DalsnaFinance › IPOs › Avalyn Pharma › IPO
Avalyn Pharma Inc. completed its initial public offering on NASDAQ on April 30, 2026, pricing at $18.00 a share.
| Ticker | AVLN |
|---|---|
| Exchange | NASDAQ |
| Status | Completed |
| Listing date | April 30, 2026 |
| Offering price | $18.00 |
| Shares offered | 16,666,667 |
| Total raised | $300M |
Avalyn Pharma Inc. sold 16,666,667 shares at $18.00 each on NASDAQ. Multiplied out, that is $300 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $300 million total recorded for the deal.
Measured by money raised, Avalyn Pharma Inc. was tied for the 88th largest (level with 11 other deals) of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. The median deal in the same window raised $200 million, so this one was about 1.5 times the typical size.
Among the 342 listings on NASDAQ alone, it is tied for the 47th largest (level with 8 other listings).
April 2026 saw 30 completed IPOs in the site's data; by amount raised, Avalyn Pharma Inc. was the 10th largest of the 30 deals with a recorded size.
Its $18.00 offer price was tied for the 82nd highest (level with 12 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Avalyn Pharma Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Avalyn Pharma Inc.. This page is general information, not investment advice.